ATR

Aptargroup

• Simply Wall St·2d ago

  How Investors May Respond To AptarGroup (ATR) Powering ENA’s Phase II Intranasal Antiviral Study

• Simply Wall St·6d ago

  Assessing AptarGroup (ATR) Valuation After Recent Share Price Weakness

• NASDAQ·03/26 09:43

  New Strong Sell Stocks for March 26th

• Simply Wall St·03/25 03:17

  Did CEO Succession and Nasal Drug Collaborations Just Shift AptarGroup's (ATR) Investment Narrative?

• Simply Wall St·03/22 06:04

  AptarGroup’s Nasal Devices Gain Ground In Respiratory Trials And Leadership Shift

• Benzinga·03/20 14:06

  Wells Fargo Upgrades AptarGroup to Overweight, Raises Price Target to $144

• Dow Jones·03/20 14:01

  AptarGroup Price Target Raised to $144.00/Share From $133.00 by Wells Fargo

• Dow Jones·03/20 14:01

  AptarGroup Raised to Overweight From Equal-Weight by Wells Fargo

• NASDAQ·03/20 09:09

  New Strong Sell Stocks for March 20th

• Benzinga·03/19 21:18

  AptarGroup Announces That Its Unidose Powder Nasal Spray System Is Being Utilized In ENA Respiratory's Phase II Clinical Study Of INNA 051

• TipRanks·03/19 21:05

  AptarGroup’s unidose powder nasal delivery system used in ENA Phase 2 study

• TipRanks·03/19 12:07

  Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR) and HeartFlow, Inc. (HTFL)

• TipRanks·03/19 12:05

  DBS Sticks to Its Buy Rating for AptarGroup (ATR)

• Benzinga·03/18 14:16

  AptarGroup Hires New CEO

• NASDAQ·03/18 09:10

  New Strong Sell Stocks for March 18th